1. Home
  2. RCKT vs PRG Comparison

RCKT vs PRG Comparison

Compare RCKT & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • PRG
  • Stock Information
  • Founded
  • RCKT 1999
  • PRG 2020
  • Country
  • RCKT United States
  • PRG United States
  • Employees
  • RCKT N/A
  • PRG N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • PRG Diversified Commercial Services
  • Sector
  • RCKT Health Care
  • PRG Consumer Discretionary
  • Exchange
  • RCKT Nasdaq
  • PRG Nasdaq
  • Market Cap
  • RCKT 328.6M
  • PRG 1.4B
  • IPO Year
  • RCKT N/A
  • PRG N/A
  • Fundamental
  • Price
  • RCKT $3.71
  • PRG $31.39
  • Analyst Decision
  • RCKT Buy
  • PRG Hold
  • Analyst Count
  • RCKT 13
  • PRG 6
  • Target Price
  • RCKT $12.88
  • PRG $35.50
  • AVG Volume (30 Days)
  • RCKT 3.3M
  • PRG 377.2K
  • Earning Date
  • RCKT 11-06-2025
  • PRG 10-22-2025
  • Dividend Yield
  • RCKT N/A
  • PRG 1.66%
  • EPS Growth
  • RCKT N/A
  • PRG 109.72
  • EPS
  • RCKT N/A
  • PRG 5.11
  • Revenue
  • RCKT N/A
  • PRG $2,518,216,000.00
  • Revenue This Year
  • RCKT N/A
  • PRG $1.44
  • Revenue Next Year
  • RCKT $3,592.75
  • PRG $3.56
  • P/E Ratio
  • RCKT N/A
  • PRG $6.15
  • Revenue Growth
  • RCKT N/A
  • PRG 5.17
  • 52 Week Low
  • RCKT $2.19
  • PRG $23.50
  • 52 Week High
  • RCKT $18.89
  • PRG $49.90
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 55.72
  • PRG 41.45
  • Support Level
  • RCKT $3.41
  • PRG $30.99
  • Resistance Level
  • RCKT $4.51
  • PRG $32.10
  • Average True Range (ATR)
  • RCKT 0.27
  • PRG 0.85
  • MACD
  • RCKT 0.07
  • PRG -0.04
  • Stochastic Oscillator
  • RCKT 43.99
  • PRG 39.64

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: